108
· DOS Abstracts
YKL-40 protein expression in osteosarcoma tumor
tissue
Andrea Thorn, Lise Hanne Christiansen, Søren Daugaard, Michael Mørk
Petersen
Musculoskeletal Tumor Section, Department of Orthopedic Surgery,
Rigshospitalet, University of Copenhagen, Denmark; Department of Pathology,
Rigshospitalet, University of Copenhagen, Denmark
Background:
YKL-40 is a glycoprotein that has showed increased expression in
several other types of cells such as cancer cells, macrophages and leukocytes,
embryonic cells, fetal cells, and cartilage cells. Previous studies have shown that
elevated serum concentrations of YKL-40 in patients with various types of can-
cer constitute an independent prognostic variable for both short recurrence-
free interval and short overall survival.
Purpose / Aim of Study:
The aim of this study is to identify if ykl-40 can
serve as a surrogate marker for prediction of the outcomes in patients with
high-grade osteosarcoma.
Materials and Methods:
All patients diagnosed with a high-malignant osteo-
sarcoma of the extremities, spine or trunk wall at the Department of Pathology,
Rigshospitalet during the years 2000-2010 were identified (n=86). Of these
48 patients (mean age 26 (6-88) years, F/M= 29/19) met criteria for inclusion
in the study based on data availability and biopsy sample size. The biopsies were
analysed by immunohistochemical analysis in order to determent the degree of
YKL-40 staining intensity in tumour tissue
Findings / Results:
All 48 biopsies were positive for YKL-40 staining with vari-
ous staining intensities. If the mean staining intensity of 24% was used to divide
the material, we found a better survival in patients with high staining intensity
(p=0.05), and the 5 and 10 years survival was 80% for patients with a staining
intensity over the mean intensity of 24% (n=15), and 48% and 43% respec-
tively, for patients with an intensity below the mean (n=33)
Conclusions:
Data indicates that a higher YKL-40 expression is connected to a
longer overall survival.
55.
